At Nexigen we aim to develop novel medicines, the NexiTides, to address an area of high unmet clinical need in oncology, the presence of so-called cancer stem cells. Cancers are very often made up of a mixture of different types of cells. Some cells divide repeatedly, while others, the cancer stem cells, self-renew (copy themselves), feed tumor growth and develop into more mature cell types that no longer divide. Cancer stem cells, therefore, can resist conventional cancer therapy to cause relapse and form metastases.
We have the key
Nexigen developed a technology to attack disease-related mechanisms deep inside cancer stem cells. With our screening technology we are able to address proteins involved in disease progression and tumor spread which other conventional cancer therapies cannot reach.
Working for a beacon of hope
Today’s ability to fight cancer is confounded by cancer stem cells and their propensity to form metastases. Specific inhibitors of cancer stem cells such as our NexiTides attack the cause for metastasis and help to overcome one of the biggest current obstacles in cancer therapy.